Short-course fluoroquinolones in acute exacerbations of chronic bronchitis

Gotfried, Mark H.; Grossman, Ronald F.

doi:10.1586/ers.10.52

Cited by 5 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results of several studies indicated that the use of later fluoroquinolones, e.g. levofloxacin, gatifloxacin and moxifloxacin, is associated with fewer relapses and longer exacerbation-free intervals as compared to first-line antibiotics used in the treatment of bacterial COPD exacerbations [36][37][38]. In the present study, we found low frequency of relapses in the study subjects with clinical remission of the exacerbation during a 20-day follow-up period which was similar in both examined groups.…”

Section: Discussionsupporting

confidence: 70%

Efficacy and safety of levofloxacin in the outpatient treatment of exacerbation of chronic obstructive pulmonary disease: levofloxacin 750 mg vs. levofloxacin 500 mg

Минов¹,

Stoleski²,

Petrova³

et al. 2020

Health Prim Car

View full text Add to dashboard Cite

Introduction: Bacterial pathogens occur in 40-60% of COPD exacerbations requiring appropriate and timely antimicrobial therapy. Aim of the study:To compare efficacy and safety of oral levofloxacin 750 mg and levofloxacin 500 mg in the outpatient treatment of moderate bacterial exacerbations of COPD. Methods:We performed an observational, non-randomized, open-label study (a real life-study) including 63 COPD patients with moderate bacterial exacerbation after treatment failure with some first-line antibiotic. They were divided in two groups: Group 1, treated 7 days with levofloxacin 750 mg once a day, and Group 2, treated 10 days with levofloxacin 500 mg once a day. All study subjects had intermediate visits at 3, 5, and 7 days (Group 1) and at 3, 5, 7, and 10 days (Group 2) at which they were evaluated about the duration of symptoms and the side-effects of the drug. Relapse rates were registered during a 20 days follow-up period in the patients with remission of the symptoms. Results:We found high clinical success rate in both Group 1 and Group 2 (84.3% and 83.9%, respectively). The mean time for clinical remission in days was significantly shorter in the study subjects treated with levofloxacin 750 mg than in the study subjects treated with levofloxacin 500 mg (5.1 ± 1.6 vs. 6.9 ± 1.8; P = 0.0001). In both Group 1 and Group 2 during the treatment was registered similar incidence of mild side effects (12.5% vs. 12.9%; P = 0.961). Incidence of relapses over a 20-day following-up period was also similar in both examined groups (7.4% vs. 7.7%; P = 0.968). Conclusion:Our findings supported the use of levofloxacin 750 mg as an alternative antibiotic in the treatment of COPD exacerbations due to its high efficacy and good tolerability.

show abstract

Section: Discussionsupporting

confidence: 70%

Efficacy and safety of levofloxacin in the outpatient treatment of exacerbation of chronic obstructive pulmonary disease: levofloxacin 750 mg vs. levofloxacin 500 mg

Минов¹,

Stoleski²,

Petrova³

et al. 2020

Health Prim Car

View full text Add to dashboard Cite

show abstract

“…These are synthetic antibacterial chemotherapeutics, with wide spectrum of action used in the treatment of illnesses caused by microorganisms, especially of alimentary, respiratory and urogenital systems diseases, as well as secondary infections in viral diseases (Martínez et al 2006, Gotfried andGrossman 2010) and in veterinary dermatology (Ihrke et al 1999, Hillier et al 2006. Among that group of compounds special attention should be paid to enrofloxacin, which belongs to the second generation of quinolones and has strong antiseptic effect and wide spectrum of action.…”

Section: Introductionmentioning

confidence: 99%

Activity of superoxide dysmutase, catalase and glutathione peroxidase in rats exposed to chlorpyrifos and erofloxacin

Barski¹,

Spodniewska²,

Zasadowski³

2011

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

The aim of the study was to investigate the influence of administration of chlorpyrifos and/or enrofloxacin on the activity of chosen antioxidative enzymes i.e.: superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) in erythrocytes of rats. Chlorpyrifos was administered by stomach tube during 28 days at a dose of 3 mg/kg bw (0.02 LD 50 ), and enrofloxacin was administered by stomach tube at a dose of 5 mg/kg bw during 3 subsequent days. It was stated that administration of enrofloxacin at applied dose did not cause any major changes in the activity of investigated antioxidative enzymes. The four-week exposure of rats to chlorpyrifos caused noticeable decrease in SOD and CAT activity in erythrocytes of rats at the beginning of the experiment (up to 24 th hour) in comparison with the control group. The activity of GPx during all periods of the experiment was increased. In the group of animals in which both chlorpyrifos and enrofloxacin were applied, the profile of changes in activity of examined enzymes was similar to that one, which was observed after administration of chlorpyrifos exclusively, what may indicate lack of co-action between compounds used in the experiment.

show abstract

“…5,6 Previous studies have investigated the efficacy and speed of recovery of short-course fluoroquinolone therapy (#5 days) in comparison with standard regimens ($7 days) and suggest that short-course regimens may be as effective as standard therapy and may offer faster resolution of symptoms, faster rate of recovery, fewer relapses, fewer and shorter hospitalizations, and longer time between recurrences. 7,8 Before this RCT, investigations of very short duration levofloxacin (,3 days) for COPD exacerbation had not been completed.…”

Section: Clinical Contextmentioning

confidence: 99%